Brigitte Fauroux

Brigitte Fauroux

Auto-generated profile, based on publicly available information

Brigitte Fauroux

Pediatric Sleep and Noninvasive Ventilation Unit AP‐HP, Hôpital Necker‐Enfants Malades Paris France

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2006 in Thorax
Verified
Journal Article
Closed access
ACA Clement
A Clement
ATA Tamalet
A Tamalet
ELE Leroux
E Leroux
SRS Ravilly
S Ravilly
BFB Fauroux
B Fauroux
JJJ-P Jais
J-P Jais
Macrolides display immunomodulatory effects that may be beneficial in chronic inflammatory pulmonary diseases. The aim of the study was to document whether long term use of azithromycin may be associated with respiratory benefits in young patients with cystic fibrosis. A multicentre, randomised, double blind, placebo controlled trial was conducted from October 2001 to June 2003. The criteria for enrollment were age older than 6 years and forced expiratory volume in 1 second (FEV1) of 40% or more. The active group received either 250 mg or 500 mg (body weight < or > or =40 kg) of oral azithromycin three times a week for 12 months. The primary end point was change in FEV1. Eighty two patients of mean (SD) age 11.0 (3.3) years and mean (SD) FEV1 85 (22)% predicted were randomised: 40 in the azithromycin group and 42 in the placebo group. Nineteen patients were infected with Pseudomonas aeruginosa. The relative change in FEV1 at month 12 did not differ significantly between the two groups. The number of pulmonary exacerbations (count ratio 0.50 (95% CI 0.32 to 0.79), p < 0.005), the time elapsed before the first pulmonary exacerbation (hazard ratio 0.37 (95% CI 0.22 to 0.63), p < 0.0001), and the number of additional courses of oral antibiotics were significantly reduced in the azithromycin group regardless of the infectious status (count ratio 0.55 (95% CI 0.36 to 0.85), p < 0.01). No severe adverse events were reported. Long term use of low dose azithromycin in young patients with cystic fibrosis has a beneficial effect on lung disease expression, even before infection with Pseudomonas aeruginosa.

1 January 2008 in Chest
Verified
Journal Article
Closed access
BFBrigitte Fauroux
Brigitte Fauroux
NGNathalie Guillemot
Nathalie Guillemot
GAGuillaume Aubertin
Guillaume Aubertin
NNNadia Nathan
Nadia Nathan
ALAgathe Labit
Agathe Labit
FLFrédéric Lofaso
Frédéric Lofaso

1 January 2010 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
ACAnnick Clement
Annick Clement
NNNadia Nathan
Nadia Nathan
RERalph Epaud
Ralph Epaud
BFBrigitte Fauroux
Brigitte Fauroux
HCHarriet Corvol
Harriet Corvol
Interstitial lung disease (ILD) in infants and children comprises a large spectrum of rare respiratory disorders that are mostly chronic and associated with high morbidity and mortality. These disorders are characterized by inflammatory and fibrotic changes that affect alveolar walls. Typical features of ILD include dyspnea, diffuse infiltrates on chest radiographs, and abnormal pulmonary function tests with restrictive ventilatory defect and/or impaired gas exchange. Many pathological situations can impair gas exchange and, therefore, may contribute to progressive lung damage and ILD. Consequently, diagnosis approach needs to be structured with a clinical evaluation requiring a careful history paying attention to exposures and systemic diseases. Several classifications for ILD have been proposed but none is entirely satisfactory especially in children. The present article reviews current concepts of pathophysiological mechanisms, etiology and diagnostic approaches, as well as therapeutic strategies. The following diagnostic grouping is used to discuss the various causes of pediatric ILD: 1) exposure-related ILD; 2) systemic disease-associated ILD; 3) alveolar structure disorder-associated ILD; and 4) ILD specific to infancy. Therapeutic options include mainly anti-inflammatory, immunosuppressive, and/or anti-fibrotic drugs. The outcome is highly variable with a mortality rate around 15%. An overall favorable response to corticosteroid therapy is observed in around 50% of cases, often associated with sequelae such as limited exercise tolerance or the need for long-term oxygen therapy.

8 July 2013 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
SKSonia Khirani
Sonia Khirani
ARAdriana Ramirez
Adriana Ramirez
GAGuillaume Aubertin
Guillaume Aubertin
MBMichèle Boulé
Michèle Boulé
CCChrystelle Chemouny
Chrystelle Chemouny
BFBrigitte Fauroux
Brigitte Fauroux

27 January 2009 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
RPRebeca Paiva
Rebeca Paiva
UKUros Krivec
Uros Krivec
GAGuillaume Aubertin
Guillaume Aubertin
ECEmmanuelle Cohen
Emmanuelle Cohen
ACAnnick Clément
Annick Clément
BFBrigitte Fauroux
Brigitte Fauroux

29 October 2007 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
NGNathalie Guillemot
Nathalie Guillemot
CTCorinne Troadec
Corinne Troadec
TVThierry Billette de Villemeur
Thierry Billette de Villemeur
ACAnnick Clément
Annick Clément
BFBrigitte Fauroux
Brigitte Fauroux